.AstraZeneca has actually utilized artificial intelligence to design an one-of-a-kind biomarker for its own Daiichi Sankyo-partnered datopotamab deruxtecan (Dato-DXd), expecting to vary the antibody-drug conjugate
Read moreAN 2 one-halfs head count, stops phase 3 test after records disappoint
.AN2 Therapies is actually reviewing its own company in feedback to uninspired midphase records, pledging to lay off half its employees and also stop a
Read moreALX’s waning CD47 reaction cost sends supply spiraling down
.ALX Oncology’s period 2 gastric cancer cells reaction fee has actually deteriorated. After finding its own CD47 blocker quickly beat control over the very first
Read moreAC Immune sees ‘site’ possible in Alzheimer’s drug data
.After more than two decades of deal with neurodegenerative diseases, Swiss biotech air conditioning Immune system claims it could have a game changer on its
Read more